

# Erratum

In the article “Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration,” [Reference: Int J Pharm Compd. 2021; 25(1): 52-61.] Table 1, row 33 states that the challenge drug was “Total Parenteral Nutrition, Hospira (Lot 87-308-DK).” This challenge drug description should be corrected to “TPN Electrolytes, Hospira (Lot 87-308-DK).”

According to the manufacturer’s package insert (NDC 0409-5779-11, Hospira, Inc.) the TPN Electrolytes, Hospira (Lot 87-308-DK) is a Multiple Electrolytes Additive containing a sterile, nonpyrogenic, concentrated solution of intra- and extracellular ions for intravenous infusion after dilution as a maintenance electrolyte replenisher only. It contains no phosphate and no bacteriostat, antimicrobial agent or added buffer. The pH is 6.6 (6.0 to 7.5). May contain hydrochloric acid for pH adjustment. The osmolar concentration is 6.2 mOsmol/mL (calc.)